Having found that the IS score reflected response to anti-CTLA-4 immunotherapies, we applied the IS to gene expression data from TCGA pan-cancer data including samples of 30 tumor types (N = 9081, Supplementary Data 3) to estimate the potential response rate of each cancer lineages to immunotherapy (Supplementary Fig. 8). The gene discussed is CTLA4; the disease is neoplasm.